Enhancing efficacy of gemcitabine in pancreatic patient-derived xenograft mouse models-Reference-Cited by-同舟云学术

Enhancing efficacy of gemcitabine in pancreatic patient-derived xenograft mouse models

Published:2020-12 Issue: Volume:2 Page:100056
ISSN:2590-1567
Container-title:International Journal of Pharmaceutics: X
language:en
Short-container-title:International Journal of Pharmaceutics: X

Author:

Inkoom Andriana,Ndemazie Nkafu,Affram Kevin,Smith Taylor,Zhu Xue,Underwood Patrick,Krishnan Sunil,Ofori Edward,Han Bo,Trevino Jose,Agyare Edward^ORCID

Funder

National Cancer Institute

National Institutes of Health

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference47 articles.

1. Smart thermosensitive liposomes for effective solid tumor therapy and in vivo imaging;Affram;PLoS One,2017

2. Pancreatic cancer chemoresistance to Gemcitabine;Amrutkar;Cancers (Basel),2017

3. Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions;Andersson;Scand. J. Gastroenterol.,2009

4. Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: an in vivo assessment in rats employing intracerebral microdialysis;Apparaju;Cancer Chemother. Pharmacol.,2008

5. Deletion of a proline-rich region and a transmembrane domain in fatty acid amide hydrolase;Arreaza;FEBS Lett.,1999

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer;BMC Cancer;2023-05-13

2. Patient-derived xenograft models in cancer therapy: technologies and applications;Signal Transduction and Targeted Therapy;2023-04-12

3. Florida-California Cancer Research, Education and Engagement (CaRE²) Health Equity Center: Structure, Innovations, and Initial Outcomes;Cancer Control;2023-04

4. Evaluation of Anticancer Activity of Zhubech, a New 5-FU Analog Liposomal Formulation, against Pancreatic Cancer;International Journal of Molecular Sciences;2023-02-21

5. Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer;BMC Cancer;2022-12-22